Table 3.
Risk Factors for Mortality
| Factor | Crude sHR (95% CI) | P Value | Adjusted sHR (95% CI) | P Value |
|---|---|---|---|---|
| TDF in regimen | <.001 | .001 | ||
| No | 1 | 1 | ||
| Yes | 1.13 (1.06–1.21) | 1.14 (1.05–1.23) | ||
| Baseline eGFR decrease | <.001 | <.001 | ||
| None | 1 | 1 | ||
| Mild | 1.19 (1.09–1.31) | 1.24 (1.12–1.37) | ||
| Moderate | 2.52 (2.16–2.94) | 1.80 (1.53–2.13) | ||
| Severe | 3.77 (2.96–4.80) | 2.00 (1.52–2.63) | ||
| Baseline CD4 count | <.001 | <.001 | ||
| <50 cells/μL | 1 | 1 | ||
| 50–199 cells/μL | 0.46 (.42–.51) | 0.60 (.56–.65) | ||
| >199 cells/μL | 0.23 (.20–.26) | 0.42 (.38–.47) | ||
| Anemia | <.001 | <.001 | ||
| None | 1 | 1 | ||
| Mild | 2.06(1.78–2.39) | 1.63 (1.45–1.83) | ||
| Moderate | 3.82 (3.32–4.40) | 2.70 (2.41–3.03) | ||
| Severe | 5.93 (1.78–2.39) | 3.88 (3.40–4.43) | ||
| Age (in years) | 1.01 (1.00–1.01) | <.001 | 1.01 (1.01–1.01) | <.001 |
| Sex | <.001 | <.001 | ||
| Male | 1 | 1 | ||
| Female | 0.81 (.75–.88) | 0.77 (.72–.83) | ||
| WHO stage | <.001 | <.001 | ||
| I or II | 1 | 1 | ||
| III | 2.34 (2.13–2.58) | 1.77 (1.62–1.93) | ||
| IV | 2.56 (2.21–2.97) | 2.12 (1.86–2.41) | ||
| Calendar year at ART start | <.001 | <.001 | ||
| 2007 | 1 | 1 | ||
| 2008 | 0.90 (.80–1.02) | 0.94 (.86–1.02) | ||
| 2009 | 0.76 (.67–.85) | 0.71 (.64–.78) | ||
| 2010 | 0.30 (.26–.34) | 0.49 (.43–.55) |
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; eGFR, estimated glomerular filtration rate; sHR, subhazard ratio; TDF, tenofovir disoproxil fumarate; WHO, World Health Organization.